210 related articles for article (PubMed ID: 30304034)
41. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
You B; Yang YL; Xu Z; Dai Y; Liu S; Mao JH; Tetsu O; Li H; Jablons DM; You L
Oncotarget; 2015 Feb; 6(6):4357-68. PubMed ID: 25738359
[TBL] [Abstract][Full Text] [Related]
42. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
43. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
44. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
45. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
46. Abnormal lipid metabolism in skeletal muscle tissue of patients with muscular dystrophy: In vitro, high-resolution NMR spectroscopy based observation in early phase of the disease.
Srivastava NK; Yadav R; Mukherjee S; Pal L; Sinha N
Magn Reson Imaging; 2017 May; 38():163-173. PubMed ID: 28069416
[TBL] [Abstract][Full Text] [Related]
47. TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.
Dutta S; Mana-Capelli S; Paramasivam M; Dasgupta I; Cirka H; Billiar K; McCollum D
EMBO Rep; 2018 Feb; 19(2):337-350. PubMed ID: 29222344
[TBL] [Abstract][Full Text] [Related]
48. miR-206 Mediates YAP-Induced Cardiac Hypertrophy and Survival.
Yang Y; Del Re DP; Nakano N; Sciarretta S; Zhai P; Park J; Sayed D; Shirakabe A; Matsushima S; Park Y; Tian B; Abdellatif M; Sadoshima J
Circ Res; 2015 Oct; 117(10):891-904. PubMed ID: 26333362
[TBL] [Abstract][Full Text] [Related]
49. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
50. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
51. A Non-Canonical Hippo Pathway Represses the Expression of ΔNp63.
Low-Calle AM; Ghoneima H; Ortega N; Cuibus AM; Katz C; Prives C; Prywes R
Mol Cell Biol; 2024 Jan; 44(1):27-42. PubMed ID: 38270135
[TBL] [Abstract][Full Text] [Related]
52. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
53. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
54. A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response.
Shao D; Zhai P; Del Re DP; Sciarretta S; Yabuta N; Nojima H; Lim DS; Pan D; Sadoshima J
Nat Commun; 2014; 5():3315. PubMed ID: 24525530
[TBL] [Abstract][Full Text] [Related]
55. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
Wang H; Di X; Bi Y; Sun S; Wang T
Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
[TBL] [Abstract][Full Text] [Related]
56. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
57. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
[TBL] [Abstract][Full Text] [Related]
58. RAP2 mediates mechanoresponses of the Hippo pathway.
Meng Z; Qiu Y; Lin KC; Kumar A; Placone JK; Fang C; Wang KC; Lu S; Pan M; Hong AW; Moroishi T; Luo M; Plouffe SW; Diao Y; Ye Z; Park HW; Wang X; Yu FX; Chien S; Wang CY; Ren B; Engler AJ; Guan KL
Nature; 2018 Aug; 560(7720):655-660. PubMed ID: 30135582
[TBL] [Abstract][Full Text] [Related]
59. Involvement of the Hippo pathway in regeneration and fibrogenesis after ischaemic acute kidney injury: YAP is the key effector.
Xu J; Li PX; Wu J; Gao YJ; Yin MX; Lin Y; Yang M; Chen DP; Sun HP; Liu ZB; Gu XC; Huang HL; Fu LL; Hu HM; He LL; Wu WQ; Fei ZL; Ji HB; Zhang L; Mei CL
Clin Sci (Lond); 2016 Mar; 130(5):349-63. PubMed ID: 26574480
[TBL] [Abstract][Full Text] [Related]
60. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
